Rhythm Pharmaceuticals, Inc.
RYTM Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$89.47
KIRA · Stoqly’s AI analyst, in plain words
- Rhythm Pharmaceuticals, Inc. had $190M of revenue in fiscal 2025, up 45.8% on the year before.
- Its operating margin was −101.2%, up 102.8 pts: of every 100 in sales, about −101 is left after running the business.
- Rhythm Pharmaceuticals, Inc. lost $197M in fiscal 2025.
- Free cash flow was −$117M in fiscal 2025, −61.5% of revenue.
- Rhythm Pharmaceuticals, Inc. has $281M more cash than debt.
Market cap
$6.1B
P/E
—
Revenue
$190M
Net income
−$197M
Free cash flow
−$117M
Operating margin
−101.2%
Rhythm Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+45.8%
Yes. Sales grew 45.8% last year.
Does it make a profit?
−103.6%
No. It lost money last year.
Does profit turn into cash?
−61.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Rhythm Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- RHYTHM PHARMACEUTICALS, INC.
- CIK
- 0001649904
Rhythm Pharmaceuticals, Inc. · RYTM
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $3.2M | $23.6M | $77.4M | $130M | $190M |
| Revenue growth | — | 649.5% | 227.6% | 68.1% | 45.8% |
| Gross margin | 81.0% | 91.0% | 88.0% | 89.7% | 89.7% |
| Operating margin | −5,391.9% | −757.9% | −238.1% | −204.0% | −101.2% |
| Net income | −$69.6M | −$181M | −$185M | −$261M | −$197M |
| Net margin | −2,207.1% | −766.2% | −238.5% | −200.3% | −103.6% |
| Diluted EPS | −$1.40 | −$3.47 | −$3.20 | −$4.34 | −$3.11 |
| Cash | |||||
| Cash from operations | −$146M | −$173M | −$136M | −$114M | −$116M |
| Capital expenditure | $0.4M | $0.3M | $0.0M | $0.0M | $1.0M |
| Free cash flow | −$146M | −$174M | −$136M | −$114M | −$117M |
| FCF margin | −4,642.9% | −734.9% | −175.9% | −87.5% | −61.5% |
| Share count change | 12.4% | 5.1% | 10.7% | 5.8% | 6.5% |
| Debt and strength | |||||
| Cash and short-term investments | $295M | $333M | $276M | $321M | $389M |
| Debt incl. finance leases | — | — | $106M | $110M | $108M |
| Shareholders' equity | $284M | $264M | $170M | $21.7M | $139M |
| Current ratio | 7.1x | 8.9x | 5.6x | 3.2x | 4.4x |
| Interest coverage | — | −34.4x | −13.3x | −12.9x | −9.3x |
| Returns and quality | |||||
| Return on capital | — | — | −260,075.1% | — | — |
| Return on equity | −30.9% | −66.1% | −85.1% | −272.2% | −244.5% |
| Return on tangible equity | −24.9% | −70.6% | −113.5% | −1,700.9% | −151.0% |
| Piotroski F-score | 2 | 4 | 2 | 4 | 6 |
| Altman Z'' | 3.1 | −1.5 | −6.4 | −9.7 | −6.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$40.1M
9 insiders
Of sales under plans
98%
$39.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Rhythm Pharmaceuticals, Inc. · RYTM
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $89.47 a share, the company is worth $6.1B.
Source: SEC EDGAR XBRL filings (CIK 0001649904). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.